Soy protein influences insulin sensitivity and cardiovascular risk in male lean SHHF rats

Hormone and Metabolic Research

Volumn 37, Issue 5, 2005, Pages 309-315

  Davis, J ^a,b   Steinle, J ^b   Higginbotham, D A ^a,b   Oitker, J ^b   Peterson, R G ^c   Banz, William J ^a,b  

^a SOUTHERN ILLINOIS UNIVERSITY   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Insulin; Metabolic syndrome; Rosiglitazone; Soy protein

Indexed keywords

ALANINE AMINOTRANSFERASE; CASEIN; CHOLESTEROL; GLUCOSE; INSULIN; ISOFLAVONE; PROTEIN; ROSIGLITAZONE; SOYBEAN PROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET; DIET RESTRICTION; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; HEART WEIGHT; HOMEOSTASIS MODEL ASSESSMENT; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; KIDNEY MASS; LEAN BODY WEIGHT; LIVER METABOLISM; LIVER WEIGHT; MALE; METABOLIC SYNDROME X; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; SCORING SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; BODY WEIGHT; CARDIOVASCULAR DISEASES; CASEINS; DIET; DIETARY PROTEINS; INSULIN; LIVER; MALE; MYOCARDIUM; RATS; RISK FACTORS; SOYBEAN PROTEINS;

ANIMALIA; RODENTIA;

EID: 21244480954     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-861475     Document Type: Article

References (59)

1. Cefalu WT. Insulin resistance: cellular and clinical concepts. Experimental Biology and Metabolism 2001; 226: 13-26
2. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiological Reviews 1995; 75: 473-485
3. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, American Heart Association; National Heart, Lung, and Blood Institute. Definition of Metabolic Syndrome. Circulation 2004; 109: 433-438
4. Reaven G, Abbasi F, McLaughlin T. Obesity insulin resistance, and cardiovascular disease. Recent Prog Horm Res 2004; 59: 207-223
5. Fonseca V. Effect of Thiazolidinediones on body weight in patients with Diabetes Mellitus. Am J Med 2003; 115: 42S-48S
6. Scheen AJ. Thiazolidinediones and liver toxicity. Diabetes Metab. 2001; 27 (3): 305-313
7. Setchell KDR. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 1998; 68 (suppl): 1333S-1346S
8. Erdman JW, Fordyce EJ. Soy products and the human diet. Am J Clin Nutr 1989; 49: 724-737
9. Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW Jr. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal woman. Am J Clin Nutr 1998; 68: 1375S-1379S
10. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Eng J Med 1995; 333: 276-282
11. Baum JA, Teng H, Erdman JW, Weigel RM, Klein BP, Persky VW, Freels S, Surya P, Bakhit RM, Ramos E, Shay NF, Potter SM. Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. Am J Clin Nutr 1998; 68: 545-551
12. Vahouny GV, Adamson I, Chalcarz W, Satchithanandam S, Muesing R, Klurfeld DM, Tepper SA, Sanghvi A, Kritchevsky D. Effects of casein and soy protein on hepatic and serum lipids and lipoprotein lipid distribution in the rat. Atherosclerosis 1985; 56: 127-137
13. Anthony MS, Clarkson TB, Williams KJ. Effects of soy isoflavones on atherosclerosis: potential mechanisms. Am J Clin Nutr 1998; 68: 1390S-1393S
14. Anthony MS, Clarkson TB, Bullock BC, Wagner JD. Soy protein versus soy phytoestrogens in the prevention of diet-induced coronary artery atherosclerosis of male cynomolgus mokeys. Atherosclerosis, Thrombosis, and Vascular Biology 1997; 17: 2524-2531
15. Maddox DA, Alavi FK, Silbernick EM, Zawada ET. Protective effects of a soy diet in preventing obesity-linked renal disease. Kidney International 2002; 61: 96-104
16. Peluso MR, Winters TA, Shanahan MF, Banz WJ. A cooperative interaction between soy protein and its isoflavone-enriched fraction lowers hepatic lipids in male obese Zucker rats and reduces blood platelet sensitivity in male Sprague-Dawley rats. J Nutr 2000; 130: 2333-2342
17. Lavigne C, Marette A, Jacques H. Cod and soy proteins compared with casein improve glucose tolerance and insulin sensitivity in rats. Endocrinology and Metabolism 2000; 278: E491-E500
18. Iritani N, Sugimoto T, Fukuda H, Komiya M, Ikeda H. Dietary soybean protein increases insulin receptor gene expression in Wistar Fatty rats when dietary polyunsaturated fatty acid level is low. J Nutr 1997; 127: 1077-1083
19. Tovar-Palacio C, Potter SM, Hafermann JC, Shay NF. Intake of soy protein and soy protein extracts influencelipid metabolism and hepatic gene expression in gerbils. J Nutr 1998; 128: 839-842
20. Dixon RA, Ferreira D. Genistein. Phytochemistry 2002; 60: 205-211
21. Crouse JR 3rd, Morgan T, Terry JG, Ellis J, Vitolins M, Burke GL. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch Intern Med 1999; 159: 2070-2076
22. Sanders TA, Dean TS, Grainger D, Miller GJ, Wiseman H. Moderate intakes of intact soy protein rich in isoflavones compared with ethanol-extracted soy protein increase HDL but do not influence transforming growth factor β1 concentrations and hemostatic risk factors for coronary heart disease in healthy subjects. Am J Clin Nutr 2002; 76: 373-377
23. Fukui K, Tachibana N, Wanezaki S, Tsuzaki S, Takamatsu K, Yamamoto T, Hashimoto Y, Shimoda T. Isoflavone-free soy protein prepared by column chromatography reduces plasma cholesterol in rats. J Agric Food Chem 2002; 50: 5717-5721
24. Jenkins DJ, Kendall CW, Jackson CJ, Connelly PW, Parker T, Faulkner D, Vidgen E, Cunnane SC, Leiter LA, Josse RG. Effects of high- and low-isoflavone soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and women. Am J Clin Nutr 2002; 76: 365-372
25. Tofovic SP, Kusaka H, Kost CK Jr, Bastacky S. Renal function and structure in diabetic, hypertensive, obese ZDFxSHHF-hybrid rats. Ren Fail 2000; 22 (4): 387-406
26. Hoversland RC. Onset of obesity and puberty in genetically obese SHHF/Mcc-cp rats. Int J Obes Relat Metab Disord 1992; 16 (12): 977-984
27. Meier DA, Hennes MM, McCune SA, Kissebah AH. Effects of obesity and gender on insulin receptor expression in liver of SHHF/Mcc-FAcp rats. Obes Res 1995; 3 (5): 465-470
28. Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993; 123: 1939-1951
29. Maddox DA, Alavi FK, Santella RN, Zawada ET Jr. Prevention of obesity-linked renal disease: age-dependent effects of dietary food restriction. Kidney Int 2002; 62 (1): 208-219
30. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28 (7): 412-419
31. Harris RB, Martin RJ. Specific depletion of body fat in parabiotic partners of tube-fed obese rats. Am J Physiol 1984; 247: R380-R386
32. Tomanek RJ, Palmer PJ, Peiffer GL, Schreiber KL, Eastham CL, Marcus ML. Morphometry of canine coronary arteries, arterioles, and capillaries during hypertension and left ventricular hypertrophy. Circ Res 1986; 58: 38-46
33. Cimini CM, Weiss HR. Microvascular morphometry and perfusion in renal hypertension-induced cardiac hypertrophy. Am J Physiol 1988; 255: H1384-H1390
34. Davis J, Higginbotham A, Iqbal J, Peterson R, Shay N, Banz W. Soy protein diets attenuate abnormalities observed in male ZDF rats. 2003 Experimental Biology meeting abstracts [accessed at http://select.biosis.org/faseb]. The FASEB Journal 18, Abstract #197.2
35. Nagasawa A, Fukui K, Funahashi T, Maeda N, Shimomura I, Kihara S, Waki M, Takamatsu K, Matsuzawa Y. Effects of soy protein diet on the expression of adipose genes and plasma adiponectin. Horm Metab Res 2002; 34(11-12): 635-639
36. Ishihara K, Oyaizu S, Fukuchi Y, Mizunoya W, Segawa K, Takahashi M, Mita Y, Fukuya Y, Fushiki T, Yasumoto K. A soybean peptide isolate diet promotes postprandial carbohydrate oxidation and energy expenditure in type II diabetic mice. J Nutr 2003; 133 (3): 752-757
37. Saito M. Effect of soy peptides on energy metabolism in obese animals [in Japanese]. Nutr. Sci. Soy Protein 1991; 12: 91-94
38. Anderson R, Wolf W. Compositional changes in trypsin inhibitor, phytic acid, saponins, and isoflavones related to soybean processing. J Nutr 1995; 125: 581-588
39. Smith SA, Lister CA, Toseland CDN, Buckingham RE. Rosiglitazone prevents the onset of hyperglycemia and proteinuria in the Zucker Diabetic Fatty rat. Diabetes, Obesity and Metabolism 2000; 2: 363-372
40. Brown KK, Henke BR, Blanchard SG, Cobb JE, Mook R, Kaldor I, Kliewer SA, Lehmann JM, Lenhard JM, Harrington WW, Novak PJ, Faison W, Binz JG, Hashim MA, Oliver WO, Brown HR, Parks DJ, Plunket KD, Tong WQ, Menius JA, Adkison K, Noble SA, Willson TM. A novel n-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker Diabetic Fatty rat. Diabetes 1999; 48: 1415-1424
41. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998; 101: 1354-1361
42. Vidal-Puig A, Jimenez-Linan M, Lowell BB, Hamann A, Hu E, Spiegelman B, Flier JS, Moller DE. Regulation of PPARγ gene expression by nutrition and obesity in rodents. J Clin Invest 1996; 97: 2553-2561
43. Yakubu-Madus FE, Stephens TW, Johnson WT. Lipid lowering explains the insulin sensitivity enhancing effects of a thizolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione. Diabetes, Obesity and Metabolism 2000; 2: 155-163
44. Smith U, Cogg S, Johansson A, Olausson T, Rotter V, Svalstedt B. Thiazolidinediones (PPARγ agonists) but not PPAR α agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. FASEB 2001; 15: 215-220
45. Zierath JR, Ryder JW, Doebber T, Woods J, Wu M, Ventre J, Li Z, McCrary C, Berger J, Zhang B, Moller DE. Role of skeletal muscle in thiazolidine-dione insulin sensitizer (PPARγ agonist) action. Endocrinology 1998; 139: 5034-5041
46. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409-435
47. Ricote M, Huang JT, Welch JS, Glass CK. The peroxisome proliferators-activated receptor-γ (PPARγ) as a regulator of monocyte/macrophage function. J Leukoc Biol 1999; 66: 733-739
48. Keller JM, Collet P, Bianchi A, Huin C, Bouillaud-Kremarik P, Becuwe P, Schohn H, Domenjoud L, Dauca M. Implications of peroxisome proliferators- activated receptors (PPARS) in development, cell life status, and disease. Int J Dev Biol 2000; 44: 429-442
49. Willson TM, Lambert MH, Kilewer SA. Peroxisome proliferator-activated receptor γ and metabolic disease. Annu Rev Biochem 2001; 70: 341-367
50. Toruner F, Akbay E, Cakir N, Sancak B, Elbeg S, Taneri F, Akturk M, Karakoc A, Ayvaz G, Arslan M. Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats. Horm Metab Res 2004; 36 (4): 226-230
51. Mezei O, Banz WJ, Steger RW, Peluso MR, Winters TA, Shay N. Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr 2003; 133: 1238-1243
52. Jeong SK, Nam HS, Rhee JA, Shin JH, Kim JM, Cho KH. Metabolic syndrome and ALT: a community study in adult Koreans. Int J Obes Relat Metab Disord 2004; 28 (8): 1033-1038
53. Hayashi U, Nagao K, Yshioka Y. Relationship between food containing "Natto" (fermented soybeans) and the blood pressure of SHR. Jpn Heart J 1976; 17: 343-344
54. Nevala R, Vaskonen T, Vehniainen J, Korpela R, Vaatalo H. Soy based diet attenuates the development of hypertension when compared with casein based diet in spontaneously hypertensive rat. Life Sci 2000; 66: 115-124
55. Martin DS, Breitkopf NP, Eyster KM, Williams JL. Dietary soy exerts an antihypertensive effect in spontaneously hypertensive female rats. Am J Physiol Regul Integr Comp Physiol 2001; 281 (2): R553-R560
56. Anderson JW, Johnstone CM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Eng J Med 1995; 333: 276-282
57. Umeda M, Kanda T, Murakami M. Effects of angiotensin II receptor antagonists on insulin resistance syndrome and leptin in sucrose-fed spontaneously hypertensive rats. Hypertens Res 2003; 26 (6): 485-492
58. Smith SA, Lister CA, Toseland CD, Buckingham RE. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes Metab 2000; 2 (6): 363-372
59. Schiffrin EL, Amiri F, Benkirane K, Iglarz M, Diep QN. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. Hypertension 2003; 42 (4): 664-668